Cancer Genetics to Host Fourth Quarter and Full Year 2017 Financial Results
March 26 2018 - 7:30AM
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision
medicine for oncology through molecular markers and diagnostics,
today announced that it will release its financial results for the
fourth quarter and full year ended December 31, 2017 on
Monday, April 2, 2018. The Company will hold a conference call at
4:30 PM Eastern on Monday, April 2, 2018 to discuss the financial
results and provide an update on its strategic direction and key
organizational improvements being made by the Company.
|
CONFERENCE CALL & WEBCAST |
Monday,
April 2, 2018, 4:30 p.m. Eastern Time |
Domestic: |
888-394-8218 |
International: |
323-701-0225 |
Conference ID: |
7874980 |
Webcast: |
http://public.viavid.com/index.php?id=128829 |
|
|
Replay –
Available through April 16, 2018 |
Domestic: |
844-512-2921 |
International: |
412-317-6671 |
Conference
ID: |
7874980 |
|
|
ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine
in oncology by partnering with leading pharmaceutical and
biotechnology companies developing novel treatments to fight cancer
and supporting physicians providing direct patient care through the
use of oncology biomarkers and molecular testing. CGI has developed
a global footprint with locations in the US, Australia, India and
China. We have established strong clinical research collaborations
with leading biopharma companies and major cancer centers such as
Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, USC
Norris Comprehensive Cancer Center,
Tisch Cancer Institute at Mount Sinai and the
National Cancer Institute among others.
The Company offers a comprehensive array of oncology-focused
services that provide critical genomic and biomarker information.
The Company’s team of medical and scientific experts delivers
clinical laboratory services from CLIA-certified and
CAP-accredited laboratories in the US with licensure from several
states, including New York State; and preclinical services,
including animal studies, from GLP-compliant audited
facilities.
For more information, please visit or follow CGI
at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to future financial
and/or operating results, future growth in revenues, margins,
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. tests and services, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or bookings or discontinuance
of trials, risks that anticipated benefits from acquisitions will
not be realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Cancer Genetics, Inc. Form 10-K for the year ended
December 31, 2016 along with other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Cancer Genetics, Inc. disclaims any obligation
to update these forward-looking statements.
INVESTOR CONTACTS:
Lee Roth / Janhavi Mohite
The Ruth Group
Tel: 646-536-7012 / 7026
Email: lroth@theruthgroup.com / jmohite@theruthgroup.com
Media:
Kirsten Thomas
The Ruth Group
Tel: 508-280-6592
Email: kthomas@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2023 to Apr 2024